|
|
|
|
| LEADER |
00000cam a2200000Mi 4500 |
| 001 |
EBOOKCENTRAL_ocn923263251 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
151010s1997 dcu o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d MERUC
|d OCLCQ
|d ZCU
|d ICG
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|d OCLCQ
|d DKC
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9780309591331
|
| 020 |
|
|
|a 0309591333
|
| 029 |
1 |
|
|a DEBBG
|b BV044107081
|
| 035 |
|
|
|a (OCoLC)923263251
|
| 050 |
|
4 |
|a RA643.O77 1997eb
|
| 082 |
0 |
4 |
|a 616.9
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Harrison, Polly F.
|
| 245 |
1 |
0 |
|a Orphans and Incentives :
|b Developing Technology to Address Emerging Infections.
|
| 260 |
|
|
|a Washington :
|b National Academies Press,
|c 1997.
|
| 300 |
|
|
|a 1 online resource (112 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Orphans and Incentives: Developing Technologies to Address Emerging Infections -- Copyright -- Preface -- THE FORUM -- THE TOPIC -- THE REPORT AND ITS ORGANIZATION -- ACKNOWLEDGMENTS -- NOTES -- Contents -- Summary -- LESSONS -- Introduction -- BACKGROUND -- THE WORKSHOP -- Workshop Summary -- THE CHILDREN'S VACCINE INITIATIVE* -- A Brief History -- Defining and Implementing Cross-Sectoral Collaboration -- Defining, Creating, and Stabilizing the Market -- Situation Analysis -- Market Segmentation -- Centralized Procurement -- Tiered Pricing
|
| 505 |
8 |
|
|a Intellectual Property and Its ProtectionTechnology Transfer -- Individual Product Experiences -- A More Heat-Stable Polio Vaccine -- The Hepatitis B Vaccine -- OTHER MODELS* -- The Malaria Vaccine Development Board -- The International AIDS Vaccine Initiative (IAVI) -- AN INDUSTRY PERSPECTIVE ON THE EMERGING INFECTIONS AGENDA* -- Industry's Response to HIV/AIDS -- The Emerging Infections Scenario and HIV/AIDS -- Barriers -- LEGAL AND REGULATORY ISSUES* -- Accelerated Approval and Development of Drugs for Serious and Life-Threatening Illnesses
|
| 505 |
8 |
|
|a Clinical StudiesSurrogate Endpoints -- Restricted Distribution and the Matter of Antimicrobial Resistance -- Product Labeling -- Product Availability -- International Harmonization of Technical Requirements to Register Pharmaceuticals -- Intellectual Property Rights Revisited -- Orphan Drug Legislation -- PUBLIC-SECTOR AGENDAS AND PRIORITIES* -- LESSONS LEARNED AND ISSUES FOR RESOLUTION -- Lessons from the Children's Vaccine Initiative -- Divergent Sectoral Mandates and Notions of Risk -- The Product Life Cycle and the Role of Market Analysis
|
| 505 |
8 |
|
|a Authentic CollaborationThe Pivotal Roles of Advocacy and Public Information -- Issues for Resolution -- Agendas and Priorities -- Funding -- Multi-Tiered Pricing -- Restricted Distribution -- Surrogate Endpoints -- Patent Extensions -- Technology Transfer and Local Production -- Orphan Drug Designation -- Other Topics -- A Final Observation -- NOTES -- APPENDIX A Emerging Infectious Diseases Research and Development Agendas: Principal Public-Sector In ... -- CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) -- R & D Priorities -- Implementation
|
| 505 |
8 |
|
|a CollaborationsBudget Allocations -- Future Challenges/Concerns/Issues -- DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA) -- R & D Priorities -- Implementation -- Collaborations -- Budget Allocations -- Future Challenges/Concerns/Issues -- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) -- R & D Priorities -- Implementation -- Collaborations -- Budget Allocations -- Future Challenges/Concerns/Issues -- UNITED STATES DEPARTMENT OF STATE (DOS) -- R & D Priorities -- Implementation -- Collaborations -- Budget Allocations
|
| 500 |
|
|
|a ""Future Challenges/Concerns/Issues""
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Emerging infectious diseases.
|
| 650 |
|
0 |
|a Communicable diseases.
|
| 650 |
|
0 |
|a Vaccines.
|
| 650 |
|
2 |
|a Communicable Diseases, Emerging
|
| 650 |
|
2 |
|a Communicable Diseases
|
| 650 |
|
2 |
|a Vaccines
|
| 650 |
|
6 |
|a Maladies infectieuses émergentes.
|
| 650 |
|
6 |
|a Maladies infectieuses.
|
| 650 |
|
6 |
|a Vaccins.
|
| 650 |
|
7 |
|a Communicable diseases
|2 fast
|
| 650 |
|
7 |
|a Emerging infectious diseases
|2 fast
|
| 650 |
|
7 |
|a Vaccines
|2 fast
|
| 700 |
1 |
|
|a Lederberg, Joshua.
|
| 776 |
0 |
8 |
|i Print version:
|a Harrison, Polly F.
|t Orphans and Incentives : Developing Technology to Address Emerging Infections.
|d Washington : National Academies Press, ©1900
|z 9780309059411
|
| 856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3376373
|z Texto completo
|
| 938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL3376373
|
| 994 |
|
|
|a 92
|b IZTAP
|
